All Categories Archives - Page 206 of 221

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension

Meghan M. Cirulis, Lynda O. Jorgensen, Ronald W. DayUniversity of Utah and Primary Children’s Hospital.United States Respiratory Medicine Case ReportsRespir Med Case Rep 2019; 28: DOI: 10.1016/j.rmcr.2019.100911 AbstractThe pulmonary arterial pressure of a child with severe pulmonary arterial hypertension immediately normalized while breathing nitric oxide during heart catheterization at 8 years of age. Her acute pulmonary […]

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension Read More »

Congenital Surfactant C Deficiency with Pulmonary Hypertension – A Case Report

Wei Chard Chua, I-Chen Chen, Yi-Ching Liu, Yen-Hsien Wu, Shih-Hsing Lo, Jong-Hau Hsu, Peir-In Liang, Hsiu-Lin Chen, Zen-Kong DaiKaohsiung Medical University Hospital. Taiwan ChildrenChildren 2022; 9: DOI: 10.3390/children9101435 AbstractInterstitial lung diseases in children are a diverse group in terms of etiology and pathogenesis. With advances in genetic testing, mutations in surfactant protein have now been identified

Congenital Surfactant C Deficiency with Pulmonary Hypertension – A Case Report Read More »

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom

Andrew Constantine, Robert M. R. Tulloh, Konstantinos Dimopoulos, Petra Jenkins, Robin Condliffe, Katrijn Jansen, Natali A. Y. Chung, James Oliver, Helen Parry, Samantha Fitzsimmons, Niki Walker, Stephen John Wort, Vasilios Papaioannou, Kate von Klemperer, Paul CliftRoyal Brompton HospitalRoyal Brompton and Harefield Hospitals. Imperial College London. Liverpool Heart and Chest Hospital. University Hospital Bristol. Royal Hallamshire

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom Read More »

Operability of atrial septal defect with borderline pulmonary vascular resistance index: A study in developing country

Oktavia Lilyasari, Rini Istisakinah, Rina Ariani, Budi Rahmat, Lies Dina Liastuti, Yovi Kurniawati, Hary Sakti Muliawan, Renan SukmawanUniversitas Indonesia and National Cardiovascular Center Harapan Kita. Indonesia Frontiers in SurgeryFront Surg 2022; 9: DOI: 10.3389/fsurg.2022.1031451 AbstractBackground: Pulmonary arterial hypertension secondary to atrial septal defect (ASD) is an important determinant of morbidity and mortality in defect closure. We aimed

Operability of atrial septal defect with borderline pulmonary vascular resistance index: A study in developing country Read More »

Deficiency in DDR1 Induces Pulmonary Hypertension and Impaired Alveolar Development

Quinn A. Bonafiglia, Yu-Qing Zhou, Guangpei Hou, Rhidita Saha, Ying-Han R. Hsu, Jonah Burke-Kleinman, Michelle P. BendeckUniversity of Toronto, Ted Rogers Centre for Heart Research and University Health Network.Canada American Journal of Respiratory Cell and Molecular BiologyAm J Respir Cell Mol Biol 2022; 67: 562-573DOI: 10.1165/rcmb.2022-0124OC AbstractPulmonary hypertension (PH) is a multifaceted condition characterized by elevated

Deficiency in DDR1 Induces Pulmonary Hypertension and Impaired Alveolar Development Read More »

Long-term outcomes of transcatheter Potts shunt in children with suprasystemic pulmonary arterial hypertension

Raymond N. Haddad, Maryline Levy, Isabelle Szezepanski, Sophie Malekzadeh-Milani, Damien BonnetHôpital Universitaire Necker-Enfants Malades and Université de Paris Cité.France Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; 9: DOI: 10.3389/fcvm.2022.1028304 AbstractBackground: Transcatheter Potts shunt (TPS) is a palliation alternative for children with severe pulmonary arterial hypertension (PAH). Debates on the long-term outcomes remain unsolved.Objectives: To evaluate long-term clinical and

Long-term outcomes of transcatheter Potts shunt in children with suprasystemic pulmonary arterial hypertension Read More »

Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension

Hannes Sallmon, Martin Koestenberger, Alexander Avian, Friedrich Reiterer, Bernhard Schwaberger, Katharina Meinel, Gerhard Cvirn, Stefan Kurath-Koller, Andreas Gamillscheg, Georg HansmannEuropean Pediatric Pulmonary Vascular Disease Network. Charité-Universitätsmedizin Berlin. Deutsches Herzzentrum Berlin. Medical University Graz. Hannover Medical School. Germany and Austria Journal of PerinatologyJ Perinatol 2022; 42: 781-787DOI: 10.1038/s41372-022-01374-w AbstractObjective: Extremely low gestational age newborns (ELGANs) represent an especially

Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension Read More »

Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH

Georg Hansmann, Franziska Diekmann, Philippe Chouvarine, Fabio Ius, Julia Carlens, Nicolaus Schwerk, Gregor Warnecke, Jens Vogel-Claussen, Dagmar Hohmann, Tim Alten, Thomas JackEuropean Pediatric Pulmonary Vascular Disease Network. Hannover Medical School. University Hospital Heidelberg.Germany Journal of Heart and Lung TransplantationJ Heart Lung Transplant 2022; 41: 187-198DOI: 10.1016/j.healun.2021.10.014 AbstractBackground: We investigated whether RV function recovers in children with pulmonary

Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH Read More »

Mesenchymal Stem Cell-derived Extracellular Vesicles Prevent Experimental Bronchopulmonary Dysplasia Complicated By Pulmonary Hypertension

Mayank Sharma, Michael A. Bellio, Merline Benny, Shathiyah Kulandavelu, Pingping Chen, Chawisa Janjindamai, Chenxu Han, Liming Chang, Shanique Sterling, Kevin Williams, Andreas Damianos, Sunil Batlahally, Kaitlyn Kelly, Daniela Aguilar-Caballero, Ronald Zambrano, Shaoyi Chen, Jian Huang, Shu Wu, Joshua M. Hare, Augusto Schmidt, Aisha Khan, Karen YoungUniversity of Miami Miller School of Medicine.United States Stem Cells Translational Medicine Stem Cells Transl Med 2022; 11: 828-840DOI: 10.1093/stcltm/szac041 AbstractMesenchymal stem cell (MSC) extracellular vesicles (EVs) have beneficial effects in preclinical bronchopulmonary

Mesenchymal Stem Cell-derived Extracellular Vesicles Prevent Experimental Bronchopulmonary Dysplasia Complicated By Pulmonary Hypertension Read More »